Mount Sinai
School of Medicine (MSSM) is employing
DiscoveryBioMed (DBM) in fee-for-service contracts covering basic drug discovery work. The agreement calls for human cell optimization, assay optimization, and drug discovery bioassays.
Experiments have reportedly commenced on assay optimization, and pilot drug screening will begin shortly. The firm is using its expertise in the development and engineering of human cell cultures and lines from normal or diseased tissue.